Anxiety disorders are a prevalent and disabling condition. Because of high rates of treatment resistance, there is interest in new pharmacological treatment options such as second-generation antipsychotics. This systematic review evaluated the efficacy and tolerability of second-generation antipsychotics in the treatment of anxiety disorders. We found eleven randomised placebo-controlled trials, comparing quetiapine, olanzapine and risperidone with placebo and antidepressants. The vast majority of the available data was on quetiapine (> 3000 participants). Participants with generalised anxiety disorder responded significantly better to quetiapine than to placebo, measured as a reduction in the Hamilton Anxiety Scale (HAM-A). Participants treated with quetiapine were more likely to drop out due to adverse events, to gain weight, to suffer from sedation or to suffer from extrapyramidal side effects. The evidence on the other second-generation antipsychotics is currently too limited to draw any conclusions.
- Fluctuations in alliance and use of techniques over time: A bidirectional relation between use of common factors techniques and the development of the working alliance
- The ethical justification for the use of non-human primates in research: the Weatherall report revisited
- Experiences of using a participatory action research approach to strengthen district local capacity in Eastern Uganda
- Climate change in the global south drives people to suicide
- Driving to Work: The Front Seat Work of Paramedics to and from the Scene
Category Specific RSS